First-in-class, preservative-free eye treatment and
tear film stabilizer in evaporative dry eye disease

Novaliq Product NovaTears AFT Lubricating Eye Drops

As the first-of-its kind, NovaTears® offers a new Mode of Action by acting as a lubricating lipid layer stabilizer and evaporative barrier for improving tear film stability and quality.

NovaTears® is clinically validated by significant improvement in signs and symptoms in evaporative dry eye disease and MGD patients (4 clinical trials).

What are the benefits of NovaTears®?

  • prevents evaporation
  • no blurring – same refractive index as water
  • excellent spreading properties on the eye
  • long duration
  • preservative-free
  • small drops size ~ 10µl
  • silky feeling

What is the regulatory status of NovaTears®?

  • In Europe the product is registered as CE-marked product under the medical device directive.
  • In New Zealand and Australia, NovaTears® has received registrational approval as medical device in October 2017.
  • In the USA, we are pursuing a New Drug Application (NDA) for NovaTears® with the next important milestone: a confirmatory phase 3 study starting in 2019.
  • In Japan, we have received the classification of NovaTears® as Medical Device from PMDA and will submit the approval dossier following a clinical study in Japan.

In which countries are NovaTears® available?

  • Europe CE-approved as EvoTears® by Ursapharm
  • Australia/NewZealand by AFT Pharmaceuticals

Are you interested in a collaborating with Novaliq?

Start typing and press Enter to search